We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Paracetamol Metabolism in Post Operative Conditions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01152502
Recruitment Status : Completed
First Posted : June 29, 2010
Last Update Posted : June 29, 2010
Sponsor:
Information provided by:
University Hospital, Clermont-Ferrand

Brief Summary:
Follow-up of urinary concentration from paracetamol metabolites by patients with aortic surgery during 4 days therapeutic intake (perfalgan ® 4 x 1g IV/day)

Condition or disease
Aortic Surgery and Treatment Post Operative With Paracetamol During 4 Days

Detailed Description:

D-15 to D0: selection

  • patient information and non-opposition obtained
  • inclusion and non inclusion criteria check
  • clinical exam

D-1 to D0 : 24 hours diuresis

D0 : operation day

Before anesthesia :

  • urine collection (paracetamol metabolites dosage)
  • blood sampling (glutathion and liver function test)

Surgery:

  • 1st paracetamol intake before closing
  • Then administration every 6 hours

D1 to D4 :

  • 24 hours urine collection (metabolites dosage)
  • blood sampling et D1 and D4(glutathion and liver function test)

D5 : final clinical exam


Study Type : Observational
Actual Enrollment : 30 participants
Time Perspective: Cross-Sectional
Official Title: Paracetamol Metabolism in Post Operative Conditions
Study Start Date : June 2008
Primary Completion Date : September 2008
Study Completion Date : June 2010



Primary Outcome Measures :
  1. Follow-up of urinary concentration from paracetamol metabolites by patients with aortic surgery during 4 days therapeutic intake (perfalgan ® 4 x 1g IV/day) [ Time Frame: during 4 days therapeutic intake ]

Secondary Outcome Measures :
  1. - Follow-up of glutathion concentration during 4 post operative days [ Time Frame: during 4 post operative days ]
  2. Monitoring of liver function


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Defined population
Criteria

Inclusion Criteria:

  • aortic surgery
  • treatment with intraveinous paracetamol (4 grammes daily during 4 days)
  • patient agrees to participate

Exclusion Criteria:

  • - patient disagrees
  • paracetamol contra-indication
  • paracetamol intake 5 days before surgery

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01152502


Locations
France
CHU Clermont-Ferrand
Clermont-Ferrand, France, 63003
Sponsors and Collaborators
University Hospital, Clermont-Ferrand
Investigators
Principal Investigator: Eric SCHNEIDER University Hospital, Clermont-Ferrand

Responsible Party: Patrick LACARIN, CHU Clermont-Ferrand
ClinicalTrials.gov Identifier: NCT01152502     History of Changes
Other Study ID Numbers: CHU-0076
First Posted: June 29, 2010    Key Record Dates
Last Update Posted: June 29, 2010
Last Verified: June 2010

Keywords provided by University Hospital, Clermont-Ferrand:
Post operative conditions, paracetamol metabolites

Additional relevant MeSH terms:
Acetaminophen
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Antipyretics